The increased use of antibacterial and antifungal agents in recent years has resulted in the
development of resistance to these drugs. The significant clinical implication of resistance …

Voriconazole (Vfend™) is a new triazole that currently is undergoing phase III clinical trials.
This review summarizes the published data obtained by NCCLS methods on the in vitro …

Biofilms, likely the predominant mode of device-related microbial infection, exhibit resistance
to antimicrobial agents. Evidence suggests that Candida biofilms have dramatically reduced …

In this study, the safety, tolerability, and pharmacokinetics of intravenous (iv)-to oral-dose
regimens of voriconazole were evaluated with a group of 42 healthy men, 41 of whom …

The growth inhibitory effect of Cymbopogon nardus (L.) W. Watson var. nardus essential oil
on Aspergillus niger (Van Tieghem) mycelium was determined on agar medium. The …

The essential oils from Thymus eriocalyx and Thymus X-porlock obtained by
hydrodistillation were analyzed by GC/MS. The major components of T. eriocalyx and T. X …

OBJECTIVE: To review the currently available information on the pharmacology,
pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage guidelines of …

The past two decades have witnessed an increase in serious fungal infections, without
corresponding growth in available antifungal agents. Voriconazole (VRC) is a novel triazole …

The purpose of this study was to assess the effect of voriconazole on the blood tacrolimus
concentration in a liver transplant recipient and to examine the interaction between …

OBJECTIVE: To review the pharmacology, in vitro susceptibility, pharmacokinetics, clinical
efficacy, and adverse effects of voriconazole, a triazole antifungal agent. DATA SOURCES …